Literature DB >> 17533532

Use of nitinol stents following recanalization of central venous occlusions in hemodialysis patients.

Dheeraj K Rajan1, Jasdeep S Saluja.   

Abstract

PURPOSE: To retrospectively review the patency of endovascular interventions with nitinol stent placement for symptomatic central venous occlusions in hemodialysis patients.
METHODS: A retrospective review of all patients who underwent endovascular interventions for dysfunctional hemodialysis grafts and fistulas was performed from April 2004 to August 2006. A total of 6 patients presented with arm and/or neck and facial swelling and left brachiocephalic vein occlusion. The study group consisted of 3 men and 3 women with a mean age of 79.5 years (SD 11.2 years). Of these 6 patients, 1 had a graft and 5 had fistulas in the left arm. The primary indication for nitinol stent placement was technical failure of angioplasty following successful traversal of occluded central venous segments. Patency was assessed from repeat fistulograms and central venograms performed when patients redeveloped symptoms or were referred for access dysfunction determined by the ultrasound dilution technique. No patients were lost to follow-up.
RESULTS: Nitinol stent placement to obtain technically successful recanalization of occluded venous segments was initially successful in 5 of 6 patients (83%). In 1 patient, incorrect stent positioning resulted in partial migration to the superior vena cava requiring restenting to prevent further migration. Clinical success was observed in all patients (100%). Over the follow-up period, 2 patients underwent repeat intervention with angioplasty alone. Primary patency was 83.3% (95% CI 0.5-1.2) at 3 months, and 66.7% at 6 and 12 months (0.2-1.1, 0.1-1.2). Secondary patency was 100% at 12 months with 3 patients censored over that time period. Mean primary patency was 10.4 months with a mean follow-up of 12.4 months. No complications related to recanalization of the occluded central venous segments were observed.
CONCLUSION: Our initial experience has demonstrated that use of nitinol stents for central venous occlusion in hemodialysis patients is associated with good mid-term patency and may exceed historical observations with prior use of Wallstents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533532     DOI: 10.1007/s00270-007-9083-9

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

1.  Stent placement versus angioplasty improves patency of arteriovenous grafts and blood flow of arteriovenous fistulae.

Authors:  Micah R Chan; Surmeet Bedi; Robert J Sanchez; Henry N Young; Yolanda T Becker; Paul S Kellerman; Alexander S Yevzlin
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

2.  Endovascular treatment of central venous obstruction as a complication of prolonged hemodialysis - Preliminary experience in a tertiary care center.

Authors:  Mukesh K Yadav; Madhurima Sharma; Anupam Lal; Vivek Gupta; Ashish Sharma; Niranjan Khandelwal
Journal:  Indian J Radiol Imaging       Date:  2015 Oct-Dec

3.  Comparison of Open-Cell Stent and Closed-Cell Stent for Treatment of Central Vein Stenosis or Occlusion in Hemodialysis Patients.

Authors:  Chae Hoon Kang; Seung Boo Yang; Woong Hee Lee; Jae Hong Ahn; Dong Erk Goo; Nae Jin Han; Joon Young Ohm
Journal:  Iran J Radiol       Date:  2016-09-11       Impact factor: 0.212

4.  The feasibility and safety of a through-and-through wire technique for central venous occlusion in dialysis patients.

Authors:  Yonghui Huang; Bing Chen; Guosheng Tan; Gang Cheng; Yi Zhang; Jiaping Li; Jianyong Yang
Journal:  BMC Cardiovasc Disord       Date:  2016-12-07       Impact factor: 2.298

5.  One-year outcomes and predictive factors for primary patency after stent placement for treatment of central venous occlusive disease in hemodialysis patients.

Authors:  Bin Chen; Run Lin; Haitao Dai; Jianyong Yang; Keyu Tang; Nan Li; Yonghui Huang
Journal:  Ther Adv Chronic Dis       Date:  2022-02-17       Impact factor: 5.091

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.